Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries has informed that the US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Limited's Halol facility (Gujarat, India) from 02 June to 13 June 2025. At the conclusion of the inspection, the US FDA issued a Form-483, with 8 observations.Powered by Capital Market - Live

Sun Pharmaceuticals Industries announced that the 33th Annual General Meeting(AGM) of the company will be held on 31 July 2025.Powered by Capital Market - Live

Profit before tax (PBT) jumped 15.6% YoY to Rs 3,254.35 crore in Q4 FY25. During the quarter, EBITDA stood at Rs 3,716.1 crore (including other operating revenues), up 22.4% with resulting EBITDA margin of 28.7%. India formulations sales were Rs 4,213 crore for Q4FY25, a growth of 13.6% over Q4 last year and accounted for 32.9% of total consolidated sales for the quarter. US formulation sales were $464 million for Q4FY25, lower by 2.5% over Q4 FY24 and accounted for 31.4% of total consolidated sales for the quarter. Formulation sales in emerging markets sales were $261 million for Q4FY25, a growth of 6.3% over Q4 last year and accounted for 17.6% of total consolidated sales for the quarter. Formulation sales in Rest of World (RoW) markets were $ 200 million for Q4FY25, a growth of 2.0% over Q4 FY24 and accounted for approximately 13.5% of total consolidated sales for the quarter. During the quarter, external sales of API were at Rs 533 crore, up 28.2%. The company said that its API portfolio supports its formulation business and API customers across geographies. During the quarter, R&D expense stood at Rs 816.6 crore, or 6.4% of sales. On full year basis, the company's consolidated net profit jumped 14.1% to Rs 10,929.04 crore on 9% increase in revenue from operations to Rs 52,041.25 crore in FY25 over FY24. The pharmaceutical company stated that it has a comprehensive product offering in the US market consisting of approved ANDAs for 542 products while filings for 117 ANDAs await US FDA approval, including 33 tentative approvals. Additionally, the portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval. For the quarter, 9 ANDA were filed and 1 ANDA approval was received. Dilip Shanghvi, chairman and managing director of the company said, 'Our businesses delivered a robust performance for the year, driven by improving market share in India and growth in Global Specialty. The near-term pipeline in Global Specialty is promising, with products such as Leqselvi and Unloxcyt'the latter through our recently announced checkpoint acquisition'offering significant improvements in patient care. We look forward to specialty becoming an increasingly important part of our business.' Meanwhile, the company's board recommended a final dividend of Rs 5.50 per share with a face value of Rs 1 each for FY25, subject to approval of shareholders' approval at the ensuing annual general meeting (AGM). The company has fixed the record date as Monday, 7 July 2025. If the dividend approved by shareholders, it shall be paid on or before Friday, 8 August 2025. Sun Pharmaceutical Industries is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.Powered by Capital Market - Live

The Board of Sun Pharmaceutical Industries at its meeting held on 22 May 2025 has noted the retirement of Sudhir Valia, Non-executive and Non-independent Director of the Company with effect from 31 July 2025. Powered by Capital Market - Live

The Board of Sun Pharmaceutical Industries at its meeting held on 22 May 2025 has approved appointment of Vidhi Shanghvi (DIN: 06497350) as Whole-time Director for a period of five years, effective from today, i.e., 22 May 2025, which shall be subject to approval of the shareholders at the ensuing Annual General Meeting. Powered by Capital Market - Live

Sun Pharmaceutical Industries has fixed 07 July 2025 as record date for payment of final dividend of Rs 5.50 per share for FY 2024-25. The dividend will be paid on or before 08 August 2025, if approved. Powered by Capital Market - Live

Securities in F&O Ban: RBL Bank, Manappuram Finance and Titagarh Railways Systems shares are banned from F&O trading on 23 May 2025 Upcoming Results: JSW Steel, Aditya Birla Fashion and Retail (ABFRL), Afcons Infrastructure, AIA Engineering, Anupam Rasayan India, Apollo Micro Systems, Ashoka Buildcon, Ashok Leyland, Azad Engineering, Balkrishna Industries, BEML, Cello World, Devyani International, Dreamfolks Services will announce their results later today. Stocks to Watch: Sun Pharmaceutical Industries' consolidated net profit declined 19% to Rs 2,149.88 crore despite a 8.5% fall in revenue from operations to Rs 12,815.58 crore in Q4 FY25 over Q4 FY24. ITC's consolidated net profit surged 285.3% to Rs 19,727.37 crore on 9.9% increase in revenue from operations (excluding excise duty) to Rs 18,565.05 crore in Q4 FY25 over Q4 FY24. Honasa Consumer reported 18% decline in consolidated net profit to Rs 24.98 crore in Q4 FY25 compared with Rs 30.48 crore in Q4 FY24. Revenue from operations jumped 13.3% YoY to Rs 533.56 crore in Q4 FY25. Grasim Industries' consolidated net profit increased 9.2% to Rs 1,545.99 crore in Q4 FY25 as compared with Rs 1,369.82 crore in Q4 FY24. Revenue from operations jumped 17.3% YoY to Rs 44,267.26 crore during the quarter ended 31st March 2025. Metro Brands reported 38.9% decline in consolidated net profit to Rs 94.75 crore in Q4 FY25 as compared with Rs 155.17 crore in Q4 FY24. Net sales jumped 10.3% YoY to Rs 642.77 crore in Q4 FY25. Deepak Fertilisers & Petrochemical Corporation's consolidated net profit jumped 23.2% to Rs 277.24 crore on 27.9% increase in net sales to Rs 2,667.35 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live

Net profit of Sun Pharmaceutical Industries declined 19.01% to Rs 2149.88 crore in the quarter ended March 2025 as against Rs 2654.58 crore during the previous quarter ended March 2024. Sales rose 8.48% to Rs 12815.58 crore in the quarter ended March 2025 as against Rs 11813.33 crore during the previous quarter ended March 2024. For the full year,net profit rose 14.12% to Rs 10929.04 crore in the year ended March 2025 as against Rs 9576.38 crore during the previous year ended March 2024. Sales rose 8.97% to Rs 52041.25 crore in the year ended March 2025 as against Rs 47758.45 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales12815.5811813.33 8 52041.2547758.45 9 OPM %29.0025.69 -29.3527.27 - PBDT4279.823567.52 20 17005.3714138.85 20 PBT3616.032917.16 24 14429.9811582.21 25 NP2149.882654.58 -19 10929.049576.38 14 Powered by Capital Market - Live

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 5.5 per equity Share (i.e. 550%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd rose 2.83% today to trade at Rs 1733.95. The BSE Healthcare index is up 1.26% to quote at 42121.45. The index is up 4.26 % over last one month. Among the other constituents of the index, ERIS Lifesciences Ltd increased 2.7% and Aurobindo Pharma Ltd added 2.67% on the day. The BSE Healthcare index went up 20.02 % over last one year compared to the 13.3% surge in benchmark SENSEX. Sun Pharmaceutical Industries Ltd has added 2.75% over last one month compared to 4.26% gain in BSE Healthcare index and 9.71% rise in the SENSEX. On the BSE, 37402 shares were traded in the counter so far compared with average daily volumes of 58835 shares in the past one month. The stock hit a record high of Rs 1960.2 on 30 Sep 2024. The stock hit a 52-week low of Rs 1376.75 on 04 Jun 2024.Powered by Capital Market - Live